Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Thousands of people were laid off Tuesday at the United States' top health agencies. Here are what positions and efforts were ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Moderna, Baxter, and Pfizer are our top healthcare picks.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...